Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could this toothpaste beat gum disease?

NCT ID NCT07169188

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a toothpaste with stannous fluoride can improve gum health better than a regular fluoride toothpaste. 154 adults with mild gum inflammation (gingivitis) used one of the two toothpastes for 12 weeks. Researchers measured gum bleeding and plaque to see which toothpaste worked better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
stannous fluoride toothpaste
What this could lead to
If it works, this toothpaste could become a simple, everyday option to reduce gum bleeding and plaque buildup.
What could go wrong
This is a small, completed study with 154 participants, so results may not apply to everyone. The improvement over regular toothpaste may be small.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

154 people

The number who actually took part.

Started

Sep 2025

Finished

Dec 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participant has provided a signed and dated informed consent document indicating that they have been informed of all pertinent aspects of the study before any assessment is performed. 2. Participant is of either biological sex and any gender. 3. Participant is, at the time of screening, aged 18-70 years, inclusive. 4. Participant is willing and able to comply with scheduled visits, treatment plan and all study procedures and Lifestyle Considerations. 5. Participant is in good general and mental health with, in the opinion of the investigator or medically qualified designee, no clinically significant or relevant abnormalities in medical history or upon oral examination, or condition, that would impact the participant's safety, wellbeing or the outcome of the study, if they were to participate in the study, or affect the individual's ability to understand and follow study procedures and requirements. 6. Participant with oral health that meets all the following: 1. At Visits 1 and 2, has at least 20 natural, permanent teeth (excluding 3rd molars) with at least 40 evaluable surfaces for MGI and TPI assessments. 2. At Visit 2, has, in the opinion of the examiner, localized plaque-induced gingivitis with 10-30% bleeding sites from the BI assessment and with an overall TPI score \>= 1.5. Exclusion Criteria: 1. Participant is an employee of the investigational site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or a Haleon employee directly involved in the conduct of the study or a member of their immediate family. 2. Participant has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days prior to study entry and/or during study participation. 3. Participant with, in the opinion of the investigator or medically qualified designee, an acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the participant inappropriate for entry into this study. 4. Participant has any other clinical serious or unstable conditions (example, cardiovascular diseases, diabetes, liver disorders, and kidney disorders) which could have affected study outcomes and/or participant safety. 5. Participant is breast feeding or is pregnant (self-reported) or intending to become pregnant over the duration of the study. 6. Participant with known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients. 7. Participant is unwilling or unable to comply with the Lifestyle Considerations described in this protocol. 8. Participant is a current or ex (stopped within 6 months of Screening) nicotine user, example, smokes, vapes or uses smokeless forms of tobacco such as chewing tobacco, gutka, pan containing tobacco, snus, tobacco pouches etc. 9. Participant has diagnosed xerostomia or is taking any medication or has a condition, that in the opinion of the investigator, is causing xerostomia. 10. Participant has a medical condition (example, bleeding disorder) which could directly influence gingival bleeding or could affect study outcomes and/or participant safety. 11. Participant who has a recent history (within the last year) of alcohol or other substance abuse. 12. Participant who has a severe oral condition (example, acute necrotizing ulcerative gingivitis or oral or peri-oral ulceration including herpetic lesions) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant/examiner if they participate in the study. 13. Participant has a tongue or lip piercing, or any other oral feature that, in the opinion of the investigator, could interfere with the proper usage of a toothbrush or with correct application of study products. 14. Participant has/is using the following medications: 1. Any antibiotic medication within 28 days prior to screening, or at any time during the study. 2. Any anti-bacterial toothpaste/mouthwash (example, chlorhexidine) or other oral care product within 2 weeks of Screening that, in the opinion of the investigator or dentally qualified designee, could affect plaque formation or gingival health. 3. Systemic medication (example, anti-inflammatories, anticoagulants, immunosuppressants, traditional/ herbal remedy etc) within 2 weeks of screening or at any point in the study, which, in the opinion of the Investigator, could affect plaque/gingival condition (example, ibuprofen, aspirin, warfarin, cyclosporin, phenytoin, calcium channel blockers). 4. A participant currently taking a systemic medication (example, anti-inflammatory, anticoagulant, immunosuppressants) or traditional/ herbal remedy which, in the opinion of the Investigator, could affect plaque/ gingival condition (example, ibuprofen, aspirin, warfarin, cyclosporin, phenytoin, calcium channel blockers). 15. Participant demonstrating the following dental conditions: 1. Signs of active periodontitis (site with probing depth over 3 mm) 2. Is receiving or has received treatment for periodontal disease (including surgery) within 12 months of Screening. 3. Has gingivitis, which in the opinion of the investigator, is not expected to respond to treatment with an over the counter (OTC) dentifrice. 4. Has active caries that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study. 5. Has dentures (partial or full) or an orthodontic appliance (bands, appliances, or fixed/ removable retainers). 6. Has received orthodontic therapy within 3 months of Screening. 7. Has numerous restorations in a poor state of repair. 8. Has any dental condition (example, overcrowding) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study. 9. Has had dental prophylaxis or tooth bleaching within 12 weeks of Screening. 10. Has high levels of extrinsic stain or calculus deposits, in the opinion of the investigator, that could have interfered with plaque assessments. 16. Participant who has previously been enrolled in this study. 17. Participant who, in the opinion of the investigator or medically qualified designee, should not participate in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dental plaque are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Dental Plaque gingivitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • All Sum Research

    Mississauga, Ontario, L5N 6J2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.